What is the debt of GlaxoSmithKline Pharmaceuticals this year?
GlaxoSmithKline Pharmaceuticals has a debt level of -194.02 INR this year.
In 2024, GlaxoSmithKline Pharmaceuticals's total debt was -194.02 INR, a -92.71% change from the -2,661 INR total debt recorded in the previous year.
GlaxoSmithKline Pharmaceuticals's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Analyzing GlaxoSmithKline Pharmaceuticals's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Investors pay close attention to GlaxoSmithKline Pharmaceuticals’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Shifts in GlaxoSmithKline Pharmaceuticals’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
GlaxoSmithKline Pharmaceuticals has a debt level of -194.02 INR this year.
The debt of GlaxoSmithKline Pharmaceuticals has increased by -92.71% compared to the previous year dropped.
High debt can pose a risk for investors of GlaxoSmithKline Pharmaceuticals, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
Low debt means that GlaxoSmithKline Pharmaceuticals has a strong financial position and is able to fulfill its obligations without overburdening its finances.
An increase in debt of GlaxoSmithKline Pharmaceuticals can adversely affect the financial condition of the company and result in a higher burden on its finances.
A reduction in debt of GlaxoSmithKline Pharmaceuticals can strengthen the company's financial position and improve its ability to meet its financial obligations.
Some factors that can influence the debt of GlaxoSmithKline Pharmaceuticals include investments, acquisitions, operating costs, and revenue development.
The debts of GlaxoSmithKline Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
To change the debt, GlaxoSmithKline Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
Over the past 12 months, GlaxoSmithKline Pharmaceuticals paid a dividend of 32 INR . This corresponds to a dividend yield of about 1.53 %. For the coming 12 months, GlaxoSmithKline Pharmaceuticals is expected to pay a dividend of 30.32 INR.
The current dividend yield of GlaxoSmithKline Pharmaceuticals is 1.53 %.
GlaxoSmithKline Pharmaceuticals pays a quarterly dividend. This is distributed in the months of August, August, August, July.
GlaxoSmithKline Pharmaceuticals paid dividends every year for the past 24 years.
For the upcoming 12 months, dividends amounting to 30.32 INR are expected. This corresponds to a dividend yield of 1.45 %.
GlaxoSmithKline Pharmaceuticals is assigned to the 'Health' sector.
To receive the latest dividend of GlaxoSmithKline Pharmaceuticals from 7/26/2023 amounting to 32 INR, you needed to have the stock in your portfolio before the ex-date on 6/30/2023.
The last dividend was paid out on 7/26/2023.
In the year 2023, GlaxoSmithKline Pharmaceuticals distributed 30 INR as dividends.
The dividends of GlaxoSmithKline Pharmaceuticals are distributed in INR.
Our stock analysis for GlaxoSmithKline Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GlaxoSmithKline Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.